Profile data is unavailable for this security.
About the company
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
- Revenue in EUR (TTM)21.27bn
- Net income in EUR2.96bn
- Incorporated1995
- Employees62.35k
- LocationMerck KGaAFrankfurter Strasse 250DARMSTADT 64293GermanyDEU
- Phone+49 6151720
- Fax+49 6 151722000
- Websitehttps://www.merckgroup.com/
Mergers & acquisitions
| Acquired company | MRKX:GER since announced | Transaction value |
|---|---|---|
| Jsr Life Sciences-Chromatography Business | 4.94% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer AG | 45.87bn | -198.00m | 36.74bn | 88.50k | -- | 1.24 | 10.80 | 0.8011 | -0.2015 | -0.2015 | 46.69 | 30.11 | 0.4344 | 1.58 | 4.52 | 494,165.80 | -0.1639 | -2.66 | -0.2205 | -3.61 | 56.35 | 57.98 | -0.3772 | -6.88 | 0.7096 | 2.33 | 0.5717 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| Alnylam Pharmaceuticals, Inc. | 3.19bn | 269.69m | 37.31bn | 2.50k | 145.78 | 54.90 | 117.51 | 11.69 | 2.25 | 2.25 | 27.82 | 5.96 | 0.8068 | 8.46 | 7.20 | 1,485,575.00 | 6.82 | -12.28 | 9.57 | -16.14 | 81.64 | 83.20 | 8.45 | -24.70 | 2.71 | 3.50 | 0.7737 | -- | 65.19 | 49.77 | 212.79 | -- | -3.56 | -- |
| Sun Pharmaceutical Industries Ltd | 5.30bn | 979.11m | 39.19bn | 43.00k | 40.06 | -- | 31.33 | 7.39 | 43.70 | 45.45 | 236.59 | -- | -- | -- | -- | 13,211,420.00 | -- | 9.09 | -- | 12.38 | 79.97 | 73.38 | 18.62 | 16.07 | -- | -- | -- | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Haleon PLC | 12.68bn | 1.92bn | 39.62bn | 24.00k | 20.90 | 2.10 | 16.89 | 3.12 | 0.185 | 0.185 | 1.22 | 1.84 | 0.3295 | 3.52 | 5.17 | -- | 5.02 | 3.99 | 5.99 | 4.64 | 64.69 | 62.89 | 15.23 | 12.64 | 0.7146 | 9.57 | 0.3431 | 30.35 | -1.81 | 2.20 | 15.60 | 7.80 | 5.37 | -- |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.86bn | 930.72m | 42.12bn | 20.24k | 45.21 | 5.91 | -- | 10.91 | 1.17 | 1.17 | 4.84 | 8.97 | 0.5312 | 1.71 | 5.75 | 1,530,951.00 | 12.82 | 12.67 | 14.40 | 14.00 | 85.49 | 85.64 | 24.14 | 20.06 | 6.20 | -- | 0.0014 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| CSL Ltd | 13.32bn | 1.21bn | 42.15bn | 32.07k | 35.00 | 2.60 | 20.31 | 3.16 | 4.08 | 4.08 | 45.05 | 55.03 | 0.4036 | 1.17 | 4.05 | 683,198.30 | 3.58 | 8.58 | 4.42 | 10.61 | 51.87 | 52.91 | 8.87 | 19.71 | 1.15 | 10.44 | 0.3525 | 47.42 | 5.12 | 11.20 | 13.63 | 7.38 | -6.11 | 7.95 |
| Zoetis Inc | 8.14bn | 2.30bn | 45.71bn | 14.50k | 20.92 | 16.07 | 16.81 | 5.62 | 6.02 | 6.02 | 21.33 | 7.84 | 0.6374 | 1.12 | 6.52 | 652,896.60 | 18.00 | 16.21 | 22.22 | 19.61 | 71.89 | 70.69 | 28.23 | 27.03 | 1.94 | 20.97 | 0.7308 | 29.07 | 2.28 | 7.24 | 7.52 | 10.29 | 6.51 | 20.11 |
| Takeda Pharmaceutical Co Ltd | 24.44bn | 618.06m | 48.84bn | 47.46k | 77.61 | 1.16 | 10.37 | 2.00 | 72.26 | 72.26 | 2,834.46 | 4,838.54 | 0.2926 | 1.17 | 6.17 | 94,080,250.00 | 0.7418 | 1.71 | 0.8772 | 2.04 | 65.33 | 67.66 | 2.54 | 5.99 | 0.6548 | 3.49 | 0.3884 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| UCB SA | 7.74bn | 1.56bn | 51.17bn | 10.12k | 32.79 | 4.61 | 24.10 | 6.61 | 8.02 | 8.02 | 39.86 | 57.09 | 0.436 | 1.42 | 4.57 | 765,147.80 | 8.78 | 5.64 | 11.30 | 7.05 | 74.29 | 71.87 | 20.13 | 14.59 | 1.04 | 15.96 | 0.1713 | 28.30 | 25.83 | 7.68 | 46.29 | 16.31 | 5.17 | -- |
| Merck KGaA | 21.27bn | 2.96bn | 53.50bn | 62.35k | 18.11 | 1.85 | 10.99 | 2.52 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
| Holder | Shares | % Held |
|---|---|---|
| First Eagle Investment Management LLCas of 03 Jun 2025 | 6.44m | 1.48% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 4.88m | 1.12% |
| Mondrian Investment Partners Ltd.as of 11 Jul 2025 | 4.01m | 0.92% |
| Amundi Asset Management SASU (Investment Management)as of 02 May 2025 | 3.95m | 0.91% |
| MFS International Singapore Pte Ltd.as of 31 Jan 2026 | 3.31m | 0.76% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 3.07m | 0.71% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 3.00m | 0.69% |
| BNP Paribas Asset Management Europe SASas of 24 Feb 2026 | 2.17m | 0.50% |
| MFS International (UK) Ltd.as of 31 Jan 2026 | 2.10m | 0.48% |
| BlackRock Investment Management LLCas of 26 Feb 2026 | 1.97m | 0.45% |
